Abstract: A method is provided for the treatment of neoplastic diseases in a mammal which comprises administering to said mammal a therapeutically effective amount of thalidomide. The method also uses a combination of thalidomide with other anti-neoplastic agents. Additionally, pharmaceutical compositions containing thalidomide and other anti-cancer agents are also provided.

Abstract: A method for treatment of malignant melanoma by administering an effective amount of thalidomide alone or in combination with other anti-melanoma drugs.

Abstract: Methods of treatment for inflammatory and autoimmune dermatoses which comprises topical and/or systemic administration of a therapeutically-effective amount of thalidomide alone or in combination with other dermatological agents.

Abstract: In accordance with the present invention, a method is provided for treating reperfusion injury, ischemia and runaway inflammatory conditions with thalidomide alone or in combination with other drugs selected from the group consisting of nitrates, beta-adrenoceptor blocking agents, anti-platelet/thrombolytic drugs, drugs acting as the arachindonic acid cascade and calcium antagonists. Pharmaceutical compositions comprising thalidomide alone or in combination with other drugs are also provided.

Abstract: A method for treating a central nervous system or peripheral nervous system cholinergic deficit state in a mammalian organism in need of such treatment, said method comprising administering to said mammal an amount of thalidomide effective in the treatment of a cholinergic deficit state and for a time sufficient to achieve a suitable blood level to treat said cholinergic deficit state.

Abstract: A method for treating insulin-resistant diabetes in mammals which comprises administering to said afflicted animals a prophylactically or therapeutically effective amount of thalidomide.

Abstract: Platinum(amine) complexes, when covalently linked to a water-soluble, biodegradable or biostable polymer, exhibit high antitumor activity at low dosages of platinum against L1210 and solid tumors. The complexes are platinum square planar complexes and octahedral structures of the formulae ##STR1## wherein A.sub.2 represents either 2 ammonia ligands, 2 monodentate amine ligands or a single bidentate amine ligand; P is either a biodegradable or a biostable but biocompatible polymer having pendent anionic groups which form covalent linkages with Pt; o is a positive integer and X is an anionic ligand.

Abstract: Bis-platinum complexes having the formula ##STR1## wherein A is a ligand having two pairs of platinum-coordinating acidic groups which are each independently a carboxylate, phenolate, sulfonate or phosphonate group, each said pair being capable of coordinating with a platinum ion to form a 5-10 membered chelate ring; Z is a water-solubilizing group; n is 0 or a positive integer, with the proviso that n is 0 only when at least one of said platinum-coordinating acidic groups is sulfonate or phosphonate or when at least one platinum ion is a Pt(IV) ion; and R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are each independently H or a C.sub.1-20 alkyl, aryl, aralkyl, or alkaryl group, or together form one or more C.sub.1-30 alkylene, cycloalkylene, arylene, aralkylene or alkarylene groups; or a pharmaceutically acceptable salt thereof, are used as readily water-soluble antitumor agents in antitumor therapy against tumors susceptible to treatment with a platinum complex.

Abstract: Bis-platinum complexes having the formula ##STR1## wherein A is a ligand having two pairs of platinum-coordinating acidic groups which are each independently a carboxylate, phenolate, sulfonate or phosphonate group, each said pair being capable of coordinating with a platinum ion to form a 5-10 membered chelate ring; Z is a water-solubilizing group; n is 0 or a positive integer, with the proviso that n is 0 only when at least one of said platinum-coordinating acidic groups is sulfonate or phosphonate or when at least one platinum ion is a Pt(IV) ion; and R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are each independently H or a C.sub.1-20 alkyl, aryl, aralkyl, or alkaryl group, or together form one or more C.sub.1-30 alkylene, cycloalkylene, arylene, aralkylene or alkarylene groups; or a pharmaceutically acceptable salt thereof, are useful as readily water-soluble antitumor agents.